reports
- Research Department
IBERIAN DAILY 12 DECEMBER (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: CELLNEX, FERROVIAL, GRUPO SANJOSE, REPSOL, TELEFÓNICA, VIDRALA. The Ibex near 17,000 points European stock markets climbed near 1% yesterday after the Fed’s rate cut and despite doubts surrounding the technology sector after the poor reception of Oracle’s results. In the STOXX 600, Construction (that rallied after being the worst-performing sector last Wednesday) and Leisure, closely followed by Banks led the gains whereas Utilities and Energy were almost the only sectors ending w...
- Research Department
INFORME DIARIO 12 DICIEMBRE (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: CELLNEX, FERROVIAL, GRUPO SANJOSE, REPSOL, TELEFÓNICA, VIDRALA. EUROPA: BNP PARIBAS. El Ibex enfila los 17.000 puntos Las bolsas europeas avanzaron ayer cerca de un 1% tras la bajada de tipos por parte de la Fed y pese a las dudas en las tecnológicas tras la mala acogida de los resultados de Oracle. En el STOXX 600, los mejores sectores fueron Construcción (rebotó tras ser el miércoles el peor sector) y Ocio seguido de cerca por los Bancos mientras...
Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expandi...
Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases Qfitlia, the first antithrombin-lowering therapy for hemophilia, can offer consistent protection with as few as six injections a yearCablivi, the first Nanobody medicine, targets acquired/immune-mediated thrombotic thrombocytopenic purpura — a rare, life-threatening blood clotting disorder Paris, December 11, 2025. The National Medical Products Administration (NMPA) in China has approved two innovative Sanofi medi...
Communiqué de presse : Qfitlia et Cablivi de Sanofi approuvés en Chine...
Communiqué de presse : Qfitlia et Cablivi de Sanofi approuvés en Chine, élargissant la prise en charge des maladies rares Qfitlia et Cablivi de Sanofi approuvés en Chine, élargissant la prise en charge des maladies rares Qfitlia, premier traitement abaissant le taux d’antithrombine pour le traitement de l’hémophilie, peut offrir une protection constante avec seulement six injections par anCablivi, le premier médicament Nanobody, cible le purpura thrombotique thrombocytopénique acquis/à médiation immunitaire — un trouble rare de la coagulation sanguine potentiellement mortel Paris, le 11 ...
- Research Department
IBERIAN DAILY 10 DECEMBER (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: CHANGES IBEX 35, GRUPO CATALANA OCCIDENTE, INDRA, SACYR. Stock markets on stand by European stock markets saw a second session of stability, awaiting the Fed’s decision to be made public tomorrow. In the STOXX 600, Insurance and Household led the gains whereas Pharma and Constructions were the worst performers. On the macro side, the ECB will propose merging the systemic risk buffer and the countercyclical capital buffer instead of reducing the capital buffers demanded of banks. I...
- Research Department
INFORME DIARIO 10 DICIEMBRE (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: CAMBIOS IBEX, GRUPO CATALANA OCCIDENTE, INDRA, SACYR. Bolsas en stand by Segunda sesión de estabilidad en las bolsas europeas, a la espera de la decisión de la Fed de mañana. En el STOXX 600, los mejores sectores fueron Seguros y Hogar mientras que Farma y Construcción quedaron con las mayores correcciones. Por el lado macro, desde el BCE se propondrá fusionar el colchón de riesgo sistémico y el colchón de capital anticíclico en lugar de reducir los...
Communiqué de presse : Sanofi finalise l’acquisition de Vicebio
Communiqué de presse : Sanofi finalise l’acquisition de Vicebio Sanofi finalise l’acquisition de Vicebio Paris, le 4 décembre 2025. Sanofi annonce aujourd’hui la finalisation de . Cette acquisition apporte à Sanofi un candidat-vaccin combiné en phase précoce de développement contre le virus respiratoire syncytial (VRS) et le métapneumovirus humain (HMPV), deux virus respiratoires, et renforce les capacités de conception et de développement de vaccins grâce à la technologie « Molecular Clamp » de Vicebio. Le candidat-vaccin acquis complète la position de Sanofi dans le domaine des vaccins ...
Press Release: Sanofi completes acquisition of Vicebio
Press Release: Sanofi completes acquisition of Vicebio Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its . This acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV), both respiratory viruses, and expands the capabilities in vaccine design and development with Vicebio’s ‘Molecular Clamp’ technology. The acquired vaccine candidate complements Sanofi’s position in respiratory vaccines. It enables Sanofi to offer increased physician and patient choice in...
Moody's Ratings assigns Ba2 instrument rating to Almirall's proposed s...
Moody's Ratings (Moody's) has today assigned a Ba2 instrument rating to the proposed €250 million backed senior unsecured notes due 2031 to be issued by Almirall, S.A. (Almirall or the company). The outlook is unchanged at stable. Proceeds from the issuance of the backed senior unsecured notes as ...
- Research Department
IBERIAN DAILY 01 DECEMBER (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: IAG, MAPFRE, SANTANDER, TELEFÓNICA. Between monetary policy and a possible Ukraine-Russia peace treaty With the only US macro reference being the Fed’s Beige Book, the markets saw a transitional week due to Black Friday. European markets ended the week with gains, rallying from support levels and seeking 2025 highs, with the Ukraine-Russia peace talks continuing to be in the spotlight. In the STOXX 600, Basic Resources and Construction led the gains, with Food and Household Goods ...
- Research Department
INFORME DIARIO 01 DICIEMBRE (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: IAG, MAPFRE, SANTANDER, TELEFÓNICA. EUROPA: AIRBUS. Entre la política monetaria y una posible paz en Ucrania/Rusia Los mercados vivieron una semana de transición por el Black Friday y ante escasas referencias macroeconómicas. A la espera de las negociaciones de Paz entre Ucrania y Rusia las bolsas europeas terminaron la semana con ganancias, buscando los máximos del año. En el STOXX 600, las ganancias fueron dirigidas por Recursos Básicos seguido de...
- Carole Braudeau
Credit Morning 11/26/2025
Celanese’s CFR downgraded by Moody’s with the outlook still negative|Plan to transfer all Auchan supermarkets to the Intermarché and Netto brands via a franchise agreement.|Mobilux: Q1 earnings down sharply but no leverage impact thanks to strong cash generation|Forvia: bids expected this week for the Interiors division, with a valuation of € 1.8-2.0bn|
- Carole Braudeau
Morning Crédit 26/11/2025
Celanese’s CFR downgraded by Moody’s with the outlook still negative|Projet de passage de tous les supermarchés Auchan sous enseigne Intermarché et Netto via un contrat de franchise|Mobilux : des résultats T1 en net repli mais sans impact levier grâce à une forte génération de cash|Forvia : des offres attendues cette semaine pour la division Interiors, avec une valorisation de 1.8-2.0 mds EUR|
- Research Department
IBERIAN DAILY 26 NOVEMBER (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: ACCIONA, ACCIONA ENERGÍA, FERROVIAL, NEINOR, TELEFÓNICA. Stock markets remain confident that the Fed will end up cutting rates European stock markets rose, welcoming higher rate cut expectations in the Fed’s next meeting, especially after the weakness of the US data released yesterday. In the STOXX 600, Construction and Retail were the best performers whereas cyclicals sectors such as Technology and Energy posted the biggest drop. On the macro side, in the US September’s retail sa...
- Research Department
INFORME DIARIO 26 NOVIEMBRE (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ACCIONA, ACCIONA ENERGÍA, FERROVIAL, NEINOR HOMES, TELEFÓNICA. EUROPA: ENI, UNICREDIT. Confianza en que la Fed terminará bajando tipos Avances en las bolsas europeas, que siguen celebrando las mayores expectativas de bajadas de tipos para la próxima reunión de la Fed, especialmente después de la debilidad de los datos estadounidenses de hoy. En el STOXX 600, los mejores sectores fueron Construcción y Retail mientras que cíclicos como Tecnología y En...
- Research Department
INFORME DIARIO 25 NOVIEMBRE (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: BANKINTER, IBERDROLA, TELEFÓNICA, VISCOFAN. El mercado coge aire Ligero rebote en las bolsas europeas, ante los progresos en las negociaciones de paz en Ucrania y las expectativas de bajadas de tipos para la próxima reunión de la Fed. En el STOXX 600, los mejores sectores fueron cíclicos como R. Básicos y Ocio mientras que Media y Hogar sufrieron las mayores correcciones. Por el lado macro, en Alemania el IFO de noviembre retrocedió de forma inespe...
- Research Department
IBERIAN DAILY 25 NOVEMBER (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: BANKINTER, IBERDROLA, TELEFÓNICA, VISCOFAN. Stock markets take a break European stock markets saw a slight rally amid progress in the peace negotiations in Ukraine and rate cut expectations in the Fed’s next meeting. In the STOXX 600, cyclicals sectors such as Basic Resources and Leisure were the best performers whereas Media and Household posted the biggest drop. On the macro side, in Germany November’s IFO fell unexpectedly, with drops in the expectations component. In Europe, v...
Press Release: Sanofi and Regeneron’s Dupixent approved as the first t...
Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIn the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite standard-of-care antihistamine treatmentDupixent, which i...
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a ...
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé comme étant le premier médicament ciblé dans l’UE depuis plus de dix ans contre l’urticaire chronique spontanée Dupixent, développé par Sanofi et Regeneron, a été approuvé comme étant le premier médicament ciblé dans l’UE depuis plus de dix ans contre l’urticaire chronique spontanée Approval based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIn the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU wh...
- Alvaro del Pozo
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.